Stay updated on Immunotherapy with Chemo in HER2-neg IBC Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy with Chemo in HER2-neg IBC Clinical Trial page.

Latest updates to the Immunotherapy with Chemo in HER2-neg IBC Clinical Trial page
- Check4 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange Detected- Added a new reference term 'Inflammatory breast carcinoma' and a Resources entry for the Genetic and Rare Diseases Information Center. - Added iRECIST guideline citation (Lancet Oncol. 2017) to the study references and removed the corresponding Erratum (Lancet Oncol. 2019).SummaryDifference0.2%

- Check32 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.0%

- Check40 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check47 days agoChange DetectedAddition and deletion of the same iRECIST reference cancel each other out, resulting in no net change to the page content. The study's design and outcome information remain unchanged.SummaryDifference0.0%

- Check68 days agoChange DetectedAdded Revision: v3.4.2; deleted government funding notice and Revision: v3.4.1.SummaryDifference0.3%

Stay in the know with updates to Immunotherapy with Chemo in HER2-neg IBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy with Chemo in HER2-neg IBC Clinical Trial page.